Cargando…

Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone

BACKGROUND: Bone grafts are required to fill a cavity created after curettage of benign lytic lesions of the bone. To avoid the problems associated at donor site with autologous bone graft, we require allograft or bone graft substitutes. We evaluated the healing of lytic lesions after hydroxyapatite...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Anil Kumar, Kumar, Praganesh, Keshav, Kumar, Singh, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705732/
https://www.ncbi.nlm.nih.gov/pubmed/26806973
http://dx.doi.org/10.4103/0019-5413.168767
_version_ 1782409070583480320
author Gupta, Anil Kumar
Kumar, Praganesh
Keshav, Kumar
Singh, Anant
author_facet Gupta, Anil Kumar
Kumar, Praganesh
Keshav, Kumar
Singh, Anant
author_sort Gupta, Anil Kumar
collection PubMed
description BACKGROUND: Bone grafts are required to fill a cavity created after curettage of benign lytic lesions of the bone. To avoid the problems associated at donor site with autologous bone graft, we require allograft or bone graft substitutes. We evaluated the healing of lytic lesions after hydroxyapatite (HA) grafting by serial radiographs. MATERIALS AND METHODS: Forty cases of benign lytic lesions of bone were managed by simple curettage and grafting using HA blocks. Commercially available HA of bovine origin (Surgiwear Ltd., Shahjahanpur, India) was used for this purpose. Mean duration of followup was 34.8 months (range 12–84 months). Mean patient age was 19.05 years (range 3–55 years). Radiological staging of graft incorporation was done as per criteria of Irwin et al. 2001. RESULTS: In our series, two cases were in stage I. A total of 11 cases were in stage II and 27 were in stage III. Graft incorporation was radiologically complete by 15 months. Clinical recovery was observed before radiological healing. The average time taken to return to preoperative function was 3 months. Recurrence was observed in giant cell tumor (n = 3) and chondromyxoid fibroma (n = 1). There was no incidence of graft rejection, collapse, growth plate disturbances or antigenic response. CONCLUSIONS: We conclude that calcium HA is biologically acceptable bone graft substitute in the management of benign lytic lesions of bone.
format Online
Article
Text
id pubmed-4705732
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47057322016-01-22 Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone Gupta, Anil Kumar Kumar, Praganesh Keshav, Kumar Singh, Anant Indian J Orthop Original Article BACKGROUND: Bone grafts are required to fill a cavity created after curettage of benign lytic lesions of the bone. To avoid the problems associated at donor site with autologous bone graft, we require allograft or bone graft substitutes. We evaluated the healing of lytic lesions after hydroxyapatite (HA) grafting by serial radiographs. MATERIALS AND METHODS: Forty cases of benign lytic lesions of bone were managed by simple curettage and grafting using HA blocks. Commercially available HA of bovine origin (Surgiwear Ltd., Shahjahanpur, India) was used for this purpose. Mean duration of followup was 34.8 months (range 12–84 months). Mean patient age was 19.05 years (range 3–55 years). Radiological staging of graft incorporation was done as per criteria of Irwin et al. 2001. RESULTS: In our series, two cases were in stage I. A total of 11 cases were in stage II and 27 were in stage III. Graft incorporation was radiologically complete by 15 months. Clinical recovery was observed before radiological healing. The average time taken to return to preoperative function was 3 months. Recurrence was observed in giant cell tumor (n = 3) and chondromyxoid fibroma (n = 1). There was no incidence of graft rejection, collapse, growth plate disturbances or antigenic response. CONCLUSIONS: We conclude that calcium HA is biologically acceptable bone graft substitute in the management of benign lytic lesions of bone. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4705732/ /pubmed/26806973 http://dx.doi.org/10.4103/0019-5413.168767 Text en Copyright: © Indian Journal of Orthopaedics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gupta, Anil Kumar
Kumar, Praganesh
Keshav, Kumar
Singh, Anant
Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title_full Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title_fullStr Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title_full_unstemmed Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title_short Hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
title_sort hydroxyapatite crystals as a bone graft substitute in benign lytic lesions of bone
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705732/
https://www.ncbi.nlm.nih.gov/pubmed/26806973
http://dx.doi.org/10.4103/0019-5413.168767
work_keys_str_mv AT guptaanilkumar hydroxyapatitecrystalsasabonegraftsubstituteinbenignlyticlesionsofbone
AT kumarpraganesh hydroxyapatitecrystalsasabonegraftsubstituteinbenignlyticlesionsofbone
AT keshavkumar hydroxyapatitecrystalsasabonegraftsubstituteinbenignlyticlesionsofbone
AT singhanant hydroxyapatitecrystalsasabonegraftsubstituteinbenignlyticlesionsofbone